{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=25", "query": { "intervention": "Repeat Testing", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 1094, "total_pages": 110, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repeat+Testing&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T00:57:48.217Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03375307", "title": "Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Genitourinary System Carcinoma", "Metastatic Bladder Carcinoma", "Metastatic Genitourinary System Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-11-03", "completion_date": "2026-12-16", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 17, "location_summary": "Encinitas, California • Irvine, California • La Jolla, California + 12 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03375307" }, { "nct_id": "NCT04579549", "title": "Repeat Testing for SARS-CoV-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "COVID-19", "Sars-CoV-2" ], "interventions": [ { "name": "Saliva Assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 464, "start_date": "2020-09-29", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579549" }, { "nct_id": "NCT04665739", "title": "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Neuroendocrine Tumor", "Functioning Lung Neuroendocrine Tumor", "Locally Advanced Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor G1", "Lung Neuroendocrine Tumor G2", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Non-Functioning Lung Neuroendocrine Tumor", "Recurrent Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-02-03", "completion_date": "2032-09-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665739" }, { "nct_id": "NCT03341975", "title": "Enhanced SexHealth Intervention to Improve Adolescent Outcomes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sexually Transmitted Diseases", "Reproductive Behavior" ], "interventions": [ { "name": "SexHealth", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Children's Mercy Hospital Kansas City", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "14 Years to 19 Years" }, "enrollment_count": 91, "start_date": "2017-12-01", "completion_date": "2020-05-01", "has_results": true, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03341975" }, { "nct_id": "NCT04668300", "title": "Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Angiosarcoma", "Metastatic Dedifferentiated Liposarcoma", "Metastatic Osteosarcoma", "Recurrent Angiosarcoma", "Recurrent Dedifferentiated Liposarcoma", "Recurrent Osteosarcoma", "Refractory Dedifferentiated Liposarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oleclumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2020-11-26", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04668300" }, { "nct_id": "NCT05738200", "title": "Nordic Hamstring Exercise After ACL Reconstruction Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "ACL Injury", "Muscle Weakness", "Neuromuscular Manifestations" ], "interventions": [ { "name": "Nordic Hamstring Exercise", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Toledo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 23, "start_date": "2018-07-07", "completion_date": "2022-07-13", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05738200" }, { "nct_id": "NCT05761171", "title": "A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged", "Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage", "Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged", "Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia", "Refractory Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Electrocardiogram", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Revumenib", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "6 Years", "sex": "ALL", "summary": "1 Month to 6 Years" }, "enrollment_count": 78, "start_date": "2024-01-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05761171" }, { "nct_id": "NCT06620302", "title": "Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Malignant Solid Neoplasm", "Recurrent Fibrolamellar Carcinoma", "Recurrent Malignant Solid Neoplasm", "Refractory Childhood Fibrolamellar Carcinoma", "Refractory Childhood Malignant Solid Neoplasm", "Refractory Fibrolamellar Carcinoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Bcl-XL Proteolysis Targeting Chimera DT2216", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 81, "start_date": "2025-06-12", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06620302" }, { "nct_id": "NCT02962869", "title": "Human Photoallergy Test (824/2016)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sunscreening Agents" ], "interventions": [ { "name": "BAY987517", "type": "DRUG" }, { "name": "Untreated skin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 53, "start_date": "2016-11-03", "completion_date": "2016-12-31", "has_results": false, "last_update_posted_date": "2018-12-13", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Piscataway, New Jersey", "locations": [ { "city": "Piscataway", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02962869" }, { "nct_id": "NCT01047631", "title": "Role of Exercise in Diastolic Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diastolic Heart Failure", "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Functional circuit training and lifestyle counseling", "type": "BEHAVIORAL" }, { "name": "Health education and independent walking", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 50, "start_date": "2008-12", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-10-25T00:57:48.217Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01047631" } ] }